Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Rhea-AI Summary

Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, has scheduled its Q2 2025 financial results announcement and corporate update for August 6, 2025, at 8:00 a.m. ET. The presentation will be accessible via live webcast in the Events and Presentations section of the company's investor relations website.

A recording of the webcast will be made available on www.arvinas.com after the event concludes.

News Market Reaction

-1.85%

23 alerts

-1.85% News Effect

+4.2% Peak in 2 hr 26 min

-$11M Valuation Impact

$595M Market Cap

0.6x Rel. Volume

On the day this news was published, ARVN declined 1.85%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $595M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the second quarter of 2025 and provide a corporate update during a live webcast on Wednesday, August 6, 2025, at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When will Arvinas (ARVN) report Q2 2025 earnings?

Arvinas will report its Q2 2025 financial results on Wednesday, August 6, 2025, at 8:00 a.m. ET.

How can I access Arvinas Q2 2025 earnings webcast?

The earnings webcast can be accessed through the Events and Presentations section on Arvinas' investor relations website.

Will there be a replay available of Arvinas Q2 2025 earnings call?

Yes, a replay of the webcast will be available on the Arvinas website (www.arvinas.com) after the event.

What does Arvinas (ARVN) specialize in?

Arvinas is a clinical-stage biotechnology company that develops a new class of drugs based on targeted protein degradation.